Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
15 hedge funds and large institutions have $10.2M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 8 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0.78% less ownership
Funds ownership: 20.03% → 19.26% (-0.78%)
1% less capital invested
Capital invested by funds: $10.3M → $10.2M (-$123K)
35% less funds holding
Funds holding: 23 → 15 (-8)
88% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Fondren Management
Houston,
Texas
|
+$1.67M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$249K |
| 3 |
Morgan Stanley
New York
|
+$247K |
| 4 |
BlackRock
New York
|
+$122K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$14.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$1.12M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$761K |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$302K |
| 4 |
SIM
Spark Investment Management
New York
|
-$198K |
| 5 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$154K |
OPNT Hedge Fund Activity: Q2 2019 in Review
15 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q2 2019, worth a combined $10.2M — down 1.2% from $10.3M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of OPNT and 1 opened new positions — a net loss of 7 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was Fondren Management, adding an estimated $1.67M. The largest seller was Broadfin Capital, exiting entirely with an estimated $1.12M sold.
- 15 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q2 2019, down from 23 in Q1 2019.
- Funds reported $10.2M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q2 2019, down 1.2% quarter-over-quarter.
- 1 fund opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q2 2019 and 8 closed out, a net change of -7 holders.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q2 2019 was Fondren Management, an estimated $1.67M added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q2 2019 was Broadfin Capital, an estimated $1.12M sold.
Based on aggregated 13F filings for Q2 2019.